公开(公告)号：EP2646431B1

公开(公告)日：2016-04-06

申请号：EP11845075.8

申请日：2011-11-11

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKARREDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07D403/02

CPC分类号： C07D403/12 ,  C07D239/42

公开(公告)号：EP2367819A2

公开(公告)日：2011-09-28

申请号：EP08879086.0

申请日：2008-12-24

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  RAJI REDDY, Rapolu ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy

IPC分类号： C07D413/06

CPC分类号： C07D413/06

摘要： The present invention provides a novel isopropyl acetate solvate form of zolmitriptan, and a process for its preparation thereof. The present invention also provides a process for preparation of zolmitriptan polymorph A. Thus, for example, zolmitriptan isopropanol solvate was dissolved in isopropyl acetate at 25 deg C, the contents were heated to reflux for 30 minutes and the separated solid was filtered, washed with isopropyl acetate to give zolmitriptan isopropyl acetate solvate.

公开(公告)号：EP2852574B1

公开(公告)日：2020-02-05

申请号：EP13793172.1

申请日：2013-05-21

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07D213/81

公开(公告)号：EP2852574A2

公开(公告)日：2015-04-01

申请号：EP13793172.1

申请日：2013-05-21

申请人： Hetero Research Foundation ,  Parthasaradhi, Reddy Bandi ,  Rathnakar Reddy, Kura ,  Muralidhara Reddy, Dasari ,  Srinivasa Rao, Thungathurthy ,  Vamsi Krishna, Bandi

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07D213/78

CPC分类号： C07D213/81

摘要： The present invention provides a novel process for the preparation of sorafenib tosylate polymorph III.

摘要翻译： 本发明提供了一种制备索拉非尼甲苯磺酸盐多晶型物III的新方法。

公开(公告)号：EP2648519A2

公开(公告)日：2013-10-16

申请号：EP11843202.0

申请日：2011-11-11

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： A01N43/54

CPC分类号： C07D401/14 ,  A61K31/506

摘要： The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.

摘要翻译： 本发明提供了一种新型盐酸尼洛替尼的结晶形式，其制备方法和包含其的药物组合物。

公开(公告)号：EP2646431A1

公开(公告)日：2013-10-09

申请号：EP11845075.8

申请日：2011-11-11

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKARREDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07D403/02

CPC分类号： C07D403/12 ,  C07D239/42

摘要： The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.

公开(公告)号：EP2714701B1

公开(公告)日：2016-07-13

申请号：EP12793409.9

申请日：2012-05-21

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07F9/6558

CPC分类号： C07F9/65583

公开(公告)号：EP2714701A2

公开(公告)日：2014-04-09

申请号：EP12793409.9

申请日：2012-05-21

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07F9/6533

CPC分类号： C07F9/65583

摘要： The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.

公开(公告)号：EP2601178A2

公开(公告)日：2013-06-12

申请号：EP11814205.8

申请日：2011-08-01

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  RAJI REDDY, Rapolu ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy ,  VAMSI KRISHNA, Bandi

IPC分类号： C07D239/72

CPC分类号： C07D405/10 ,  C07D405/04

摘要： The present invention provides novel dioxalate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel monobesylate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of monohydrate form of lapatinib ditosylate. The present invention further provides a process for the preparation of anhydrous form of lapatinib ditosylate.

摘要翻译： 本发明提供了拉帕替尼的新型二恶烷酸盐，其制备方法和包含其的药物组合物。 本发明还提供了新颖的拉帕替尼的单伯酯盐，其制备方法和包含它的药物组合物。 本发明进一步提供了制备拉帕替尼二磺酸一水合物形式的方法。 本发明还提供了制备无水形式的拉帕替尼二甲磺酸盐的方法。

公开(公告)号：EP2373643A2

公开(公告)日：2011-10-12

申请号：EP09836178.5

申请日：2009-01-02

申请人： Hetero Research Foundation

发明人： PARTHASARADHI REDDY, Bandi ,  RATHNAKAR REDDY, Kura ,  RAJI REDDY, Rapolu ,  MURALIDHARA REDDY, Dasari ,  SRINIVASA RAO, Thungathurthy

IPC分类号： C07D403/06

CPC分类号： C07D403/06

摘要： The present invention provides a novel crystalline form of sunitinib malate, process for its preparation and to pharmaceutical composition containing it. The present invention also provides a process for preparation of sunitinib malate crystal form I. Thus, for example, sunitinib malate was added to water, the mixture was heated to 80 deg C to obtain a clear solution and stirred for 30 minutes at 80 deg C, slowly cooled to room temperature and the solution was subjected to freez drying at about -90 deg C for 8 hours to give sunitinib malate crystalline form III.